Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
University of Basel seeks a PhD student to lead machine learning for a pediatric lung health project, integrating clinical data, breath metabolomics, biomarkers, and environmental exposure data. The role spans infancy to adolescence, with external validation across cohorts.
You will publish in ML and clinical/respiratory venues, work with clinicians and data scientists, and contribute to reproducible code and open science practices. The position starts November 2026 or upon agreement.
Department of Biomedical Engineering (DBE), University of Basel
Group:Analytics & Informatics for Child Health (AICH) in collaboration with University Children's Hospital Basel (UKBB)
Starting date:November 2026 or upon agreement
Duration:4 years
The Analytics & Informatics for Child Health (AICH) group develops AI/ML methods, digital tools, and secure data pipelines to advance pediatric healthcare. We work at the intersection of clinical medicine, machine learning, and data-intensive research, collaborating closely with hospitals, clinical IT teams, and research partners at the University of Basel.
Preterm birth affects around 14 million infants each year and is a major risk factor for lifelong respiratory disease. Current definitions of bronchopulmonary dysplasia (BPD) are categorical and predict long-term outcomes poorly. Robust early-life markers to identify infants at the highest risk of prematurity-associated lung disease (PLD) are lacking.
This project uses the Basel-Bern Infant Lung Development (BILD) cohort, which combines infant lung function, breath metabolomics, urine oxidative stress markers, clinical history, high-resolution air pollution exposure, and longitudinal lung function follow-up into adolescence. The goal is a continuous, physiology-based risk stratification framework to replace categorical BPD definitions, and to inform a respiratory follow-up program for preterm children in Switzerland.
The PhD student will lead the machine learning component: integrating clinical, physiological, environmental, and biomarker data to identify early-life signatures, aetiotypes, and treatable traits of PLD, with external validation in cohorts from Italy and Australia.